[1]	Chan SL, Sun HC, Xu Y, et al. The lancet commission on addressing the global hepatocellular carcinoma burden: Comprehensive strategies from prevention to treatment[J]. Lancet, 2025, 406(10504): 731-778. DOI: 10.1016/S0140-6736(25)01042-6. Cited in this article [1]

[2]	Taddei TH, Brown DB, Yarchoan M, et al. Critical update: AASLD practice guidance on prevention,diagnosis,and treatment of hepatocellular carcinoma[J]. Hepatology, 2025, 82(1):272-274. DOI: 10.1097/HEP.0000000000001269. Cited in this article [1]

[3]	Moon AM, Weiss NS, Beste LA, et al. No association between screening for hepatocellular carcinoma and reduced cancer-related mortality in patients with cirrhosis[J]. Gastroenterology, 2018, 155(4):1128-1139.e6. DOI: 10.1053/j.gastro.2018.06.079. Cited in this article [1]

[4]	Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and balad-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients[J]. Clin Gastroenterol Hepatol, 2016, 14(6):875-886.e6. DOI: 10.1016/j.cgh.2015.12.042. Cited in this article [1]

[5]	Yang T, Xing H, Wang G, et al. A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B[J]. Clin Chem, 2019, 65(12):1543-1553. DOI: 10.1373/clinchem.2019.308965. Cited in this article [1]

[6]	Wang MD, Diao YK, Yao LQ, et al. Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma[J]. ILIVER, 2024, 3(1): 100083. DOI: 10.1016/j.iliver.2024.100083. Cited in this article [3]

[7]	Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1):6. DOI: 10.1038/s41572-020-00240-3. Cited in this article [1]

[8]	Cai J, Chen L, Zhang Z, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma[J]. Gut, 2019, 68(12):2195-2205. DOI: 10.1136/gutjnl-2019-318882. Cited in this article [1]

[9]	Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer[J]. Nat Rev Clin Oncol, 2017, 14(9):531-548. DOI: 10.1038/nrclinonc.2017.14. Cited in this article [1]

[10]	Stejskal P, Goodarzi H, Srovnal J, et al. Circulating tumor nucleic acids: Biology,release mechanisms,and clinical relevance[J]. Mol Cancer, 2023, 22(1):15. DOI: 10.1186/s12943-022-01710-w. Cited in this article [1]

[11]	Totoki Y, Tatsuno K, Covington KR, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes[J]. Nat Genet, 2014, 46(12): 1267-1273. DOI: 10.1038/ng.3126. Cited in this article [1]

[12]	Nault JC, Mallet M, Pilati C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions[J]. Nat Commun, 2013, 4: 2218. DOI: 10.1038/ncomms3218. Cited in this article [1]

[13]	Chen L, Zhang C, Xue R, et al. Deep whole-genome analysis of 494 hepatocellular carcinomas[J]. Nature, 2024, 627(8004):586-593. DOI: 10.1038/s41586-024-07054-3. Cited in this article [2]

[14]	Sharma R, Alharbi SN, Ellum K, et al. Deep sequencing of circulating tumour DNA as a biomarker of clinical outcome to transarterial chemoembolisation in hepatocellular carcinoma[J]. NPJ Precis Oncol, 2025, 9(1): 214. DOI: 10.1038/s41698-025-00961-2. Cited in this article [1]

[15]	Zviran A, Schulman RC, Shah M, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring[J]. Nat Med, 2020, 26(7):1114-1124. DOI: 10.1038/s41591-020-0915-3. Cited in this article [1]

[16]	Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA[J]. Ann Oncol, 2020, 31(6): 745-759. DOI: 10.1016/j.annonc.2020.02.011. Cited in this article [2]

[17]	Saeki I, Suehiro Y, Yamauchi Y, et al. Methylated sept9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma[J]. Hepatol Int, 2023, 17(5): 1289-1299. DOI: 10.1007/s12072-023-10488-y. Cited in this article [1]

[18]	Chalasani NP, Ramasubramanian TS, Bhattacharya A, et al. A novel blood-based panel of methylated DNA and protein markers for detection of early-stage hepatocellular carcinoma[J]. Clin Gastroenterol Hepatol, 2021, 19(12):2597-2605.e4. DOI: 10.1016/j.cgh.2020.08.065. Cited in this article [1]

[19]

Yang T, Wang N, Wang F, et al. Refinement and validation of a comprehensive clinical diagnostic model (gamad) based on gender,age,multitarget circulating tumour DNA methylation signature and commonly used serological biomarkers for early detection of hepatocellular carcinoma: A multicentre,prospective observational study protocol[J]. BMJ Open, 2023, 13(9): e076467. DOI: 10.1136/bmjopen-2023-076467. Cited in this article [1]

[20]	Yang T, Wang M, Wang N, et al. Cost-effective identification of hepatocellular carcinoma from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers[J]. Adv Sci (Weinh), 2025, 12(19):e2411945. DOI: 10.1002/advs.202411945. Cited in this article [1]

[21]	Jiang P, Sun K, Peng W, et al. Plasma DNA end-motif profiling as a fragmentomic marker in cancer,pregnancy,and transplantation[J]. Cancer Discov, 2020, 10(5): 664-673. DOI: 10.1158/2159-8290.CD-19-0622. Cited in this article [1]

[22]	Foda ZH, Annapragada AV, Boyapati K, et al. Detecting liver cancer using cell-free DNA fragmentomes[J]. Cancer Discov, 2023, 13(3): 616-631. DOI: 10.1158/2159-8290.CD-22-0659. Cited in this article [1]

[23]	Shen H, Liu J, Chen K, et al. Language model enables end-to-end accurate detection of cancer from cell-free DNA[J]. Brief Bioinform, 2024, 25(2): bbae053. DOI: 10.1093/bib/bbae053. Cited in this article [1]

[24]	Sun Y, Zhou J, Fan J, et al. Single-cell RNA sequencing reveals spatial heterogeneity and immune evasion of circulating tumor cells[J]. Cancer Biol Med, 2021, 18(4): 934-936. DOI: 10.20892/j.issn.2095-3941.2021.0466. Cited in this article [1]

[25]	Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells,disease progression,and survival in metastatic breast cancer[J]. N Engl J Med, 2004, 351(8): 781-791. DOI: 10.1056/NEJMoa040766. Cited in this article [1]

[26]	Ozkumur E, Shah AM, Ciciliano JC, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells[J]. Sci Transl Med, 2013, 5(179): 179ra47. DOI: 10.1126/scitranslmed.3005616. Cited in this article [1]

[27]	Court CM, Hou S, Winograd P, et al. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma[J]. Liver Transpl, 2018, 24(7): 946-960. DOI: 10.1002/lt.25062. Cited in this article [1]

[28]	Zhan X, Wu R, Kong XH, et al. Elevated neutrophil extracellular traps by hbv-mediated s100a9-tlr4/rage-ROS cascade facilitate the growth and metastasis of hepatocellular carcinoma[J]. Cancer Commun (Lond), 2023, 43(2): 225-245. DOI:10.1002/cac2.12388. Cited in this article [1]

[29]	von Felden J, Garcia-Lezana T, Dogra N, et al. Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer[J]. Gut,2021: gutjnl-2021-325036. DOI: 10.1136/gutjnl-2021-325036. Cited in this article [1]

[30]	Kalluri R, LeBleu VS. The biology,function,and biomedical applications of exosomes[J]. Science, 2020, 367(6478): eaau6977. DOI: 10.1126/science.aau6977 Cited in this article [1]

[31]	Zhang Y, Xi H, Nie X, et al. Assessment of mir-212 and other biomarkers in the diagnosis and treatment of hbv-infection-related liver diseases[J]. Curr Drug Metab, 2019, 20(10): 785-798. DOI: 10.2174/1389200220666191011120434. Cited in this article [1]

[32]	Wang Y, Zhang C, Zhang P, et al. Serum exosomal micrornas combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma[J]. Cancer Med, 2018, 7(5): 1670-1679. DOI: 10.1002/cam4.1390. Cited in this article [1]

[33]	Liu W, Hu J, Zhou K, et al. Serum exosomal mir-125b is a novel prognostic marker for hepatocellular carcinoma[J]. Onco Targets Ther, 2017, 10: 3843-3851. DOI: 10.2147/OTT.S140062. Cited in this article [1]

[34]	Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer[J]. Nature, 2015, 523(7559): 177-182. DOI: 10.1038/nature14581. Cited in this article [1]

[35]	Wang M, Chang W, Zhang Y. Artificial intelligence for the diagnosis and management of cancers: Potentials and challenges[J]. MedComm (2020),2025, 6(11):e70460. DOI: 10.1002/mco2.70460. Cited in this article [1]

[36]	Park J, Lee YT, Agopian VG, et al. Liquid biopsy in hepatocellular carcinoma: Challenges,advances,and clinical implications[J]. Clin Mol Hepatol, 2025, 31(suppl): 255-284. DOI: 10.3350/cmh.2024.0541. Cited in this article [1]

[37]	Chen X, Gole J, Gore A, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test[J]. Nat Commun, 2020, 11(1): 3475. DOI: 10.1038/s41467-020-17316-z. Cited in this article [1]

[38]	Deng Z, Ji Y, Han B, et al. Early detection of hepatocellular carcinoma via no end-repair enzymatic methylation sequencing of cell-free DNA and pre-trained neural network[J]. Genome Med, 2023, 15(1): 93. DOI: 10.1186/s13073-023-01238-8. Cited in this article [1]

[39]	Guo DZ, Huang A, Wang YC, et al. Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study[J]. Clin Transl Med, 2024, 14(5): e1652. DOI: 10.1002/ctm2.1652. Cited in this article [1]

[40]	Xia TY, Zhou ZH, Meng XP, et al. Predicting microvascular invasion in hepatocellular carcinoma using ct-based radiomics model[J]. Radiology, 2023, 307(4): e222729. DOI: 10.1148/radiol.222729. Cited in this article [1]

[41]	王昊, 赵鹏飞, 吕晗, 等. 数智化时代的医学影像学推动普通外科高质量发展[J]. 中国实用外科杂志, 2026, 46(1): 11-14. DOI:10.19538/j.cjps.issn1005-2208.2026.01.03. Cited in this article [1]

[42]	Gao R, Zhao S, Aishanjiang K, et al. Deep learning for differential diagnosis of malignant hepatic tumors based on multi-phase contrast-enhanced CT and clinical data[J]. J Hematol Oncol, 2021, 14(1): 154. DOI: 10.1186/s13045-021-01167-2. Cited in this article [1]

[43]	Saillard C, Schmauch B, Laifa O, et al. Predicting survival after hepatocellular carcinoma resection using deep learning on histological slides[J]. Hepatology, 2020, 72(6): 2000-2013. DOI: 10.1002/hep.31207. Cited in this article [1]

[44]	Kiani A, Uyumazturk B, Rajpurkar P, et al. Impact of a deep learning assistant on the histopathologic classification of liver cancer[J]. NPJ Digit Med, 2020, 3: 23. DOI: 10.1038/s41746-020-0232-8. Cited in this article [1]

[45]	Cheng N, Ren Y, Zhou J, et al. Deep learning-based classification of hepatocellular nodular lesions on whole-slide histopathologic images[J]. Gastroenterology, 2022, 162(7): 1948-1961.e7. DOI: 10.1053/j.gastro.2022.02.025. Cited in this article [1]

[46]	Xu X, Zhang HL, Liu QP, et al. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma[J]. J Hepatol, 2019, 70(6): 1133-1144. DOI: 10.1016/j.jhep.2019.02.023. Cited in this article [1]

[47]	Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test[J]. Science, 2018, 359(6378): 926-930. DOI: 10.1126/science.aar3247. Cited in this article [1]

[48]	Lin N, Lin Y, Xu J, et al. A multi-analyte cell-free dna-based blood test for early detection of hepatocellular carcinoma[J]. Hepatol Commun, 2022, 6(7): 1753-1763. DOI: 10.1002/hep4.1918. Cited in this article [1]

[49]	Qu C, Wang Y, Wang P, et al. Detection of early-stage hepatocellular carcinoma in asymptomatic hbsag-seropositive individuals by liquid biopsy[J]. Proc Natl Acad Sci USA, 2019, 116(13): 6308-6312. DOI: 10.1073/pnas.1819799116. Cited in this article [1]

[50]	Yang M, Zhao Y, Li C, et al. Multimodal integration of liquid biopsy and radiology for the noninvasive diagnosis of gallbladder cancer and benign disorders[J]. Cancer Cell, 2025, 43(3): 398-412.e4. DOI: 10.1016/j.ccell.2025.02.011. Cited in this article [1]

[51]	Hashimoto T, Nakamura Y, Fujisawa T, et al. The scrum-MONSTAR cancer-omics ecosystem: striving for a quantum leap in precision medicine[J]. Cancer Discov, 2024, 14(11): 2243-2261. DOI: 10.1158/2159-8290.CD-24-0206. Cited in this article [1]

[52]

Roy D, Xu J, Taggart DJ, et al. A prospective clinical trial to evaluate the performance of a multi-analyte blood test for early detection of hepatocellular carcinoma among at-risk patients with liver cirrhosis: the cliMB study[J]. J Clin Oncol, 2023, 41(suppl4): TPS617-TPS617. DOI: 10.1200/JCO.2023.41.4_suppl.TPS617. Cited in this article [1]

[53]

Taggart D, Mahajan S, Gallant M, et al. Lbo-006 A prospective,blinded,multicenter u.s. evaluation of a multianalyte blood-based test for the detection of hepatocellular carcinoma (hcc) in patients with cirrhosis[J]. J Hepatol, 2024,80: s11. DOI:10.1016/s0168-8278(24)00441-0. Cited in this article [1]

[54]	Wang Y, Chi S, Tian Y, et al. Construction of an artificially intelligent model for accurate detection of HCC by integrating clinical,radiological,and peripheral immunological features[J]. Int J Surg, 2025, 111(4): 2942-2952. DOI: 10.1097/JS9.0000000000002281. Cited in this article [1]

[55]	Heitzer E, Haque IS, Roberts C, et al. Current and future perspectives of liquid biopsies in genomics-driven oncology[J]. Nat Rev Genet, 2019, 20(2): 71-88. DOI: 10.1038/s41576-018-0071-5. Cited in this article [1]

[56]	Katsman E, Orlanski S, Martignano F, et al. Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from nanopore sequencing[J]. Genome Biol, 2022, 23(1): 158. DOI: 10.1186/s13059-022-02710-1. Cited in this article [1]

[57]	Zhang X. Highly effective batch effect correction method for rna-seq count data[J]. Comput Struct Biotechnol J, 2025, 27: 58-64. DOI: 10.1016/j.csbj.2024.12.010. Cited in this article [1]

[58]	Wang J. Combat-met: Adjusting batch effects in DNA methylation data[J]. NAR Genom Bioinform, 2025, 7(2): lqaf062. DOI: 10.1093/nargab/lqaf062. Cited in this article [1]

[59]	Topol EJ. High-performance medicine: The convergence of human and artificial intelligence[J]. Nat Med, 2019, 25(1): 44-56. DOI: 10.1038/s41591-018-0300-7. Cited in this article [1]

[60]	Razavi P, Li BT, Brown DN, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants[J]. Nat Med, 2019, 25(12): 1928-1937. DOI: 10.1038/s41591-019-0652-7. Cited in this article [1]

[61]	Gaube S, Suresh H, Raue M, et al. Do as AI say: Susceptibility in deployment of clinical decision-aids[J]. NPJ Digit Med, 2021, 4(1): 31. DOI: 10.1038/s41746-021-00385-9. Cited in this article [1]

[62]	Lundberg SM, Erion G, Chen H, et al. From local explanations to global understanding with explainable AI for trees[J]. Nat Mach Intell, 2020, 2(1): 56-67. DOI: 10.1038/s42256-019-0138-9. Cited in this article [1]

[63]

Barr Kumarakulasinghe N, Blomberg T, Liu J, et al. Evaluating local interpretable model-agnostic explanations on clinical machine learning classification models[C]//2020 IEEE 33rd International Symposium on Computer-Based Medical Systems (CBMS). New York: IEEE,2020:7-12. DOI: 10.1109/CBMS49503.2020.00009. Cited in this article [1]

[64]	Zhang Y, Liu C, Liu M, et al. Attention is all you need: Utilizing attention in ai-enabled drug discovery[J]. Brief Bioinform, 2023, 25(1): bbad467. DOI: 10.1093/bib/bbad467. Cited in this article [1]

[65]	Chen L, Wu T, Fan R, et al. Cell-free DNA testing for early hepatocellular carcinoma surveillance[J]. EBioMedicine, 2024, 100: 104962. DOI: 10.1016/j.ebiom.2023.104962. Cited in this article [1]